Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial ...

The CDC no longer recommends routine Covid-19 booster immunisation or the combined use of the varicella and MMR jabs.

Italy-based biotech firm NanoPhoria Bioscience has announced the initial closing of its Series A funding round, raising ...

The lifting of the FDA’s clinical hold on Neurizon’s drug will pave the way for its investigation in the HEALEY-ALS trial.

Chiesi Group and Arbor have formed an exclusive partnership and licensing deal for the latter’s investigational gene editing ...

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m ...

Support services are fundamentally important to CDMS vendor selection. Consider the story of this complex rescue study when ...

Induced pluripotent stem cells (iPSCs) have the potential to usher in a new era of transformative medical treatments, capable ...

Through the FDA's ANDA scheme, drug manufacturers who test and produce their generic medicines on US soil can now seek ...

The completion of the Series A marks a fast-moving year for Trogenix, which only emerged from stealth in November 2024. The ...

Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD) ...

This culminated in a $500m funding cut to mRNA vaccine research funding, impacting around 22 projects being run at the ...